



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Hossain et al.  
Serial No. : 10/520,699  
Filed : January 7, 2005  
Title : NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES

Art Unit : Unknown  
Examiner : Aulakh Charanjit  
Conf. No. : 9528

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request. Copies of International Search Reports for WO 2005/037814, WO 2005/040167, WO 2005/049620, WO 2005/054249 and WO 2005/061499 are also enclosed.

Applicants provide a listing below of commonly owned co-pending U.S. patent applications that are included on the PTO-1449. Please note that the commonly owned co-pending U.S. patent applications were filed as U.S. national phase patent applications under 35 U.S.C. §371, and therefore the listing includes a reference to the PCT publication number for each of the commonly owned co-pending U.S. patent applications.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL 980032463 US

November 13, 2006  
Date of Deposit

Applicant : Hossain et al.  
Serial No. : 10/520,699  
Filed : January 7, 2005  
Page : 2 of 2

Attorney's Docket No.: 06275-427US1 / 100684-1P US

The PTO-1449 lists the commonly owned co-pending U.S. patent applications by their corresponding published PCT publication number.

<u>U.S. Patent Application Serial No./ Published U.S. Patent Application</u>	<u>Corresponding Published PCT Patent Application</u>
10/575,522	WO 2005/037814
10/575,525	WO 2005/040167
10/579,545	WO 2005/049620
10/581,171	WO 2005/054249
10/583,468	WO 2005/061499

This statement is being filed with a Preliminary Amendment and before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 06275-427US1.

Respectfully submitted,


Date:

November 13, 2006

Catherine M. McPartland Reg. No. 34,819  
Janis K. Fraser, Ph.D., J.D.  
Reg. No. 34,819

59.301

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-427US1	Application No. 10/520,699
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Hossain et al.	
		Filing Date January 7, 2005	Group Art Unit 1624

### U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	4,010,201	03/01/1977	Lednicer			
	AB	4,263,317	04/21/1981	Martin et al.			

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AC	EP0417631A2	03/20/1991	Europe				
	AD	EP1061076B1	12/20/2000	Europe				
	AE	WO 92/10096	06/25/1992	WIPO				
	AF	WO 96/36625	11/21/1996	WIPO				
	AG	WO 01/30780 A2	05/03/2001	WIPO				
	AH	WO 02/102387 A1	12/27/2002	WIPO				
	AI	WO03/037271 A2	05/08/2003	WIPO				
	AJ	WO 04/005295 A1	01/15/2004	WIPO				
	AK	WO 05/037814	04/28/2005	WIPO				
	AL	WO 05/040167	05/06/2005	WIPO				
	AM	WO 05/049620	06/02/2005	WIPO				
	AN	WO 05/054249	06/16/2005	WIPO				
	AO	WO 05/061499	07/07/2005	WIPO				

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AP	Mehrotra et al., "Spirocyclic Nonpeptide Glycoprotein IIb-IIIa Antagonists. Part 3: Synthesis and SAR of Potent and Specific 2,8-Diazaspiro[4.5]decanes", Bioorganic & Medicinal Chemistry Letters 12:1103-1107 (2002)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	